°µÍø³Ô¹Ï

$76.3 Million
Neoleukin Therapeutics
Confidentially Marketed Follow-On Offering
Active Bookrunner
$69.1 Million
Otonomy, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$40.0 Million
Leap Therapeutics
Confidentially Marketed Follow-On Offering
Active Bookrunner
$346.8 Million
ChemoCentryx, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$50.0 Million
Menlo Therapeutics Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$111.0 Million
Evofem Biosciences, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$100.0 Million
BioCryst Pharmaceuticals, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$45.0 Million
Ocular Therapeutix, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$60.0 Million
Gamida Cell Ltd.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$132.0 Million
Akebia Therapeutics, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
Subscribe to Active Bookrunner

© 2025 °µÍø³Ô¹Ï. Since 1895. All rights reserved.